澳大利亞GroPep www.gropep.com.au www.novozymes.com
GroPep由澳大利亞聯(lián)邦科學(xué)與工業(yè)研究組織和Adelaide 大學(xué)聯(lián)合創(chuàng)立于1988年.公司主要研發(fā)促進(jìn)細(xì)胞生長(zhǎng)的新產(chǎn)品,并工業(yè)化生產(chǎn)向世界各地銷售.公司的制藥廠主要經(jīng)營(yíng):細(xì)胞培養(yǎng),藥品研發(fā),生物試劑和合作生產(chǎn).
細(xì)胞培養(yǎng):GroPep的生長(zhǎng)因子產(chǎn)品適合藥廠使用大量細(xì)胞培養(yǎng)生產(chǎn)各種治療藥物,疫苗和抗體時(shí)所需.產(chǎn)品包括:
LongRIGF-I
LongEGF and LongTGF-α
Long是其商標(biāo)之一.
生物試劑-包括生長(zhǎng)因子,抗體和相關(guān)蛋白:
Accessory Products 
Aquaculture 
EGF / Betacellulin / TGF-α Family 
Growth Hormones 
IGF Binding Proteins (IGFBP) 
IGF Family 
NGF Family 
Receptors 
TGF-beta Family
 GroPep was founded in 1988 by CSIRO (the Australian Government's Commonwealth Scientific and Industrial Research Organisation) and the University of Adelaide. 

2006 
In December 2006 GroPep was acquired by the Danish company Novozymes A/S and became Novozymes GroPep Limited. 
2005 
Continued strong financial performance with record growth in net profit before tax to $3.1 million, more than triple that reported in 2004. One-off tax benefits lifted profit, after tax to $6.4 million. Marketing arrangements for Cell Culture Products were transferred from CSL Limited to Sigma-Aldrich Corporation (USA) by CSL's sale of its JRH Biosciences subsidiary.
2004 
Achieved a significant turnaround in financial performance to record a profit of $1.0 million and operating cash flow of $3.8 million. Commenced a $3 million facility upgrade to support our rapidly growing cell culture business.
2003 
Biotech Australia assets disposed of and on-going business consolidated to Adelaide.
2002 
GroPep acquired assets and on-going business of Sydney-based Biotech Australia Pty. Ltd.
2001 
GroPep launched a new clinical trial at the Peter MacCallum Cancer Institute in Melbourne for a chemotherapy side-effect treatment.
Pre-clinical development of a treatment for recurrent miscarriage and other unexplained infertility conditions in humans was begun.
GroPep is a founding shareholder of TGR BioSciences Pty Ltd, which was incorporated in June 2001.
2000 
GroPep relocated staff and operations to a manufacturing, R&D and administration building at Thebarton in suburban Adelaide.
GroPep successfully launches its business on the Australian Stock Exchange (Code: GRO).
1999 
GroPep became a founding shareholder in Primegro® Ltd, a company established to commercialise agricultural and veterinary uses of growth factor technology.
1998 
GroPep established its Pharmaceutical Drug Development business to develop pharmaceutical products through Phase I and II clinical trials.
1997 
The Australian Government renewed The Cooperative Research Centre (CRC) grant for a further seven years.
GroPep and Flinders University joined the original partners of the CRC, and GroPep gained exclusive rights to commercialise intellectual property developed by staff in the CRC.
1993 
GroPep commenced the production of its new recombinant variant of IGF-I (LONG®R³IGF-I). This product is marketed as a replacement for insulin in cell culture media, and is the basis of the Company's Cell Culture business.
1992 
GroPep commenced the manufacture of IGFs and related reagents and marketed them worldwide for research purposes. This is the basis of the Company's Biotechnology Reagents business.
1991 
GroPep becomes the commercial arm of the Australian Government funded 'Cooperative Research Centre (CRC) for Tissue Growth and Repair'. Commonwealth Scientific and Industrial Research Organisation (CSIRO), University of Adelaide, Child Health Research Institute (CHRI) and Dairy Research and Development Corporation (DRDC) held equity in both the CRC and GroPep.
1988 
GroPep was founded to commercialise intellectual property relating to a novel insulin-like growth factor (IGF) developed through a scientific collaboration between the Commonwealth Scientific and Industrial Research Organisation (CSIRO) and the University of Adelaide.